non-chemo nice tas - gloshospitals.nhs.uk€¦ · status of nice tas & hsts on gloucestershire...
TRANSCRIPT
Status of NICE TAs & HSTs on Gloucestershire Joint Formulary
No. NICE TA (click to open link) Compliant (Y/N)
Location on Formulary
TA1 Wisdom teeth - removal Not drug related
TA2 Hip disease - replacement prostheses Not drug related
TA10 Asthma (children under 5) - inhaler devices Y N/A adult Formulary
TA17 Colorectal cancer - laparoscopic surgery Not drug related
TA20 Motor neurone disease - riluzole (TA20) Y Chapter 4
TA23 Brain cancer - temozolomide Y No chapter 8
TA24 Wound care - debriding agents replaced by CG74 Surgical site infection
TA25 Pancreatic cancer - gemcitabine Y No chapter 8
TA26 Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine replaced by CG121
TA29 Leukaemia (lymphocytic) - fludarabine Y No chapter 8
TA30 Breast cancer - taxanes (review) replaced by CG81
TA32 Multiple sclerosis - beta interferon and glatiramer acetate (TA32) Y No chapter 8
TA34 Breast cancer - trastuzumab Y No chapter 8
TA35 Arthritis (juvenile idiopathic) - etanercept replaced by TA373
TA36 Rheumatoid arthritis - etanercept and infliximab replaced by TA130 and TA195
TA38 Asthma (older children) - inhaler devices Y N/A adult Formulary
TA40 Crohn's disease - infliximab replaced by TA187
TA42 Growth hormone deficiency (children) - human growth hormone replaced by TA188
TA43 Schizophrenia - atypical antipsychotics replaced by CG82
TA44 Hip disease - metal on metal hip resurfacing replaced by TA304
TA47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94)
Y Chapter 2
TA48 Renal failure - home versus hospital haemodialysis Not drug related
TA49 Central venous catheters - ultrasound locating devices Not drug related
TA52 Myocardial infarction - thrombolysis Y Chapter 2
TA53 Diabetes (types 1 and 2) - long acting insulin analogues (TA53) replaced by NG17
TA54 Breast cancer - vinorelbine replaced by CG81
TA55 Ovarian cancer - paclitaxel (review) Y No chapter 8
TA59 Electroconvulsive therapy (ECT) Not drug related
TA60 Diabetes (types 1 and 2) - patient education models Not drug related
TA61 Colorectal cancer - capecitabine and tegafur uracil Y No chapter 8
TA62 Breast cancer - capecitabine replaced by CG81
TA64 Growth hormone deficiency (adults) - human growth hormone (TA64) Y Chapter 6
TA65 Non-Hodgkin's lymphoma - rituximab Y No chapter 8
TA67 Flu prevention - amantadine and oseltamivir replaced by TA158
TA68 Macular degeneration (age-related) - photodynamic therapy Not drug related
TA69 Cervical cancer - cervical screening (review) Not drug related
TA70 Leukaemia (chronic myeloid) - imatinib Y No chapter 8
TA71 Ischaemic heart disease - coronary artery stents Not drug related
TA73 Angina and myocardial infarction - myocardial perfusion scintigraphy Not drug related
TA74 Trauma - fluid replacement therapy Not drug related
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75) Y No chapter 8
TA76 Epilepsy (adults) - newer drugs replaced by CG137 Epilepsy
TA77 Insomnia - newer hypnotic drugs (TA77) Y Chapter 4
TA78 Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation Not drug related
TA79 Epilepsy (children) - newer drugs replaced by CG137 Epilepsy
TA80 Acute coronary syndromes - clopidogrel (TA80) Replaced by CG94
TA81 Atopic dermatitis (eczema) - topical steroids (TA81) Y Incorporated into local guidance
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82) Y Chapter 13
TA83 Hernia - laparoscopic surgery (review) Not drug related
TA85 Renal transplantation - immuno-suppressive regimens (adults) Y No chapter 8
TA86 Gastrointestinal stromal tumours - imatinib Y No chapter 8
TA88 Bradycardia - dual chamber pacemakers Not drug related
TA89 Cartilage injury - autologous chondrocyte implantation (ACI) (review) Not drug related
TA90 Vascular disease - clopidogrel and dipyridamole replaced by TA210
TA92 Tooth decay - HealOzone Not drug related
TA94 Cardiovascular disease - statins (TA94) replaced by CG181
TA95 Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) Not drug related
TA96 Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96) Y No infections chapter
TA97 Depression and anxiety - computerised cognitive behavioural therapy (CCBT) Not drug related
TA98 Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98)
Y Chapter 4
TA99 Renal transplantation - immunosuppressive regimens for children and adolescents Y No chapter 8
TA100 Colon cancer (adjuvant) - capecitabine and oxaliplatin Y No chapter 8
TA101 Prostate cancer (hormone-refractory) - docetaxel Y No chapter 8
TA102 Conduct disorder in children - parent-training/education programmes Not drug related
TA103 Psoriasis - efalizumab and etanercept (TA103) Y Chapter 13
TA104 Psoriatic arthritis - etanercept and infliximab replaced by TA199
TA105 Colorectal cancer - laparoscopic surgery (review) Not drug related
TA106 Hepatitis C - peginterferon alfa and ribavirin (TA106) Y No chapter 8
TA107 Breast cancer (early) - trastuzumab replaced by CG80
TA108 Breast cancer (early) - paclitaxel replaced by CG80
TA109 Breast cancer (early) - docetaxel replaced by CG80
TA110 Follicular lymphoma - rituximab replaced by TA243
TA112 Breast cancer (early) - hormonal treatments Y No chapter 8
TA113 Diabetes (type 1 and 2) - inhaled insulin Withdrawn
TA114 Drug misuse - methadone and buprenorphine (TA114) Y Chapter 4
TA115 Drug misuse - naltrexone (TA115) Y Chapter 4
TA116 Breast cancer - gemcitabine Y No chapter 8
TA117 Hyperparathyroidism - cinacalcet (TA117) Y No chapter 9
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab Y No chapter 8
TA119 Leukaemia (lymphocytic) - fludarabine Negative recommendation
TA120 Heart failure - cardiac resynchronisation Not drug related
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide Y No chapter 8
TA122 Ischaemic stroke (acute) - alteplase (TA122) Replaced by TA264
TA123 Smoking cessation - varenicline (TA123) Y Chapter 4
TA124 Lung cancer (non-small-cell) - pemetrexed Y No chapter 8
TA125 Psoriatic arthritis (moderate to severe) - adalimumab replaced by TA199
TA126 Rheumatoid arthritis (refractory) - rituximab replaced by TA195
TA127 Multiple sclerosis - natalizumab (TA127) Y No chapter 8
TA128 Haemorrhoid - stapled haemorroidopexy Not drug related
TA129 Multiple myeloma - bortezomib Y No chapter 8
TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130) Replaced by TA375
TA131 Asthma (in children) - corticosteroids Y Incorporated into chapter
TA132 Hypercholesterolaemia - ezetimibe (TA132) Replaced by TA385
TA133 Asthma (uncontrolled) - omalizumab (TA133) Replaced by TA278
TA134 Psoriasis - infliximab (TA134) Y Chapter 13
TA135 Mesothelioma - pemetrexed disodium Y No chapter 8
TA136 Structural neuroimaging in first-episode psychosis Not drug related
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab Y No chapter 8
TA138 Asthma (in adults) - corticosteroids (TA138) Y Incorporated into chapter
TA139 Sleep apnoea - continuous positive airway pressure (CPAP) Not drug related
TA140 Ulcerative colitis (subacute manifestations) - infliximab (TA140) Negative recommendation
TA141 Rheumatoid arthritis (refractory) - abatacept replaced by TA195
TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142)
replaced by TA323
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143) replaced by TA383
TA145 Head and neck cancer - cetuximab Y No chapter 8
TA146 Psoriasis - adalimumab (TA146) Y Chapter 13
TA147 Breast cancer (advanced & metastatic) - bevacizumab (withdrawn) replaced by TA214
TA148 Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) Terminated
TA149 Glioma (recurrent) - carmustine implants (terminated appraisal) Terminated
TA150 Colorectal cancer (metastatic) - cetuximab (terminated appraisal) Terminated
TA151 Diabetes - insulin pump therapy (TA151) Y Chapter 6
TA152 Coronary artery disease - drug-eluting stents Not drug related
TA153 Hepatitis B - entecavir (TA153) Y No infections chapter
TA154 Hepatitis B - telbivudine (TA154) Negative recommendation
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155) Y Chapter 11
TA156 Pregnancy (rhesus negative women) - routine anti-D (review) Not drug related
TA157 Venous thromboembolism - dabigatran (TA157) Y Chapter 2
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158) Y No infections chapter
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation Not drug related
TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal
women
Y Chapter 6
TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in
postmenopausal women
Y Chapter 6
TA162 Lung cancer (non-small-cell) - erlotinib replaced by TA374
TA163 Ulcerative colitis (acute exacerbations) - infliximab (TA163) Y Chapter 1
TA164 Hyperuricaemia - febuxostat (TA164) Y Chapter 10
TA165 Organ preservation (renal) - machine perfusion and static storage Not drug related
TA166 Hearing impairment - cochlear implants Not drug related
TA167 Abdominal aortic aneurysm - endovascular stent-grafts Not drug related
TA168 Influenza - zanamivir, amantadine and oseltamivir (review) (TA168) Y No infections chapter
TA169 Renal cell carcinoma - sunitinib Y No chapter 8
TA170 Venous thromboembolism - rivaroxaban (TA170) Y Chapter 2
TA171 Multiple myeloma - lenalidomide Y No chapter 8
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab Y No chapter 8
TA173 Hepatitis B - tenofovir disoproxil fumarate (TA173) Y No infections chapter
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab Y No chapter 8
TA175 Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) Replaced by TA374
TA176 Colorectal cancer (first line) - cetuximab Y No chapter 8
TA177 Eczema (chronic) - alitretinoin (TA177) Y Chapter 13
TA178 Renal cell carcinoma Negative recommendation
TA179 Gastrointestinal stromal tumours - sunitinib Y No chapter 8
TA180 Psoriasis - ustekinumab (TA180) Y Chapter 13
TA181 Lung cancer (non-small-cell, first line treatment) - pemetrexed Y No chapter 8
TA182 Acute coronary syndrome - prasugrel (TA182) replaced by TA317
TA183 Cervical cancer (recurrent) - topotecan Y No chapter 8
TA184 Lung cancer (small-cell) - topotecan Y No chapter 8
TA185 Soft tissue sarcoma - trabectedin Y No chapter 8
TA186 Rheumatoid arthritis - certolizumab pegol (TA186) replaced by TA375
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187) Y Chapter 1
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review) Y Chapter 6
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) Negative recommendation
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance) Y No chapter 8
TA191 Gastric cancer (advanced) - capecitabine Y No chapter 8
TA192 Lung cancer (non-small-cell, first line) - gefitinib Y No chapter 8
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab Y No chapter 8
TA194 Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated
appraisal)
Terminated
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195) Y Chapter 10
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant) replaced by TA326
TA197 Atrial fibrillation - dronedarone (TA197) Y Chapter 2
TA198 Rheumatoid arthritis - tocilizumab replaced by TA247
TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199) Y Chapter 10
TA200 Hepatitis C - peginterferon alfa and ribavirin (TA200) Y No infections chapter
TA201 Asthma (in children) - omalizumab replaced by TA278
TA202 Chronic lymphocytic leukaemia - ofatumumab Negative recommendation
TA203 Diabetes (type 2) - liraglutide (TA203) replaced by NG28
TA204 Osteoporotic fractures - denosumab (TA204) replaced by CG175
TA205 Thrombocytopenic purpura - eltrombopag (TA205) replaced by TA293
TA206 Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) Terminated
TA207 Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) Terminated
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab Y No chapter 8
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib Negative recommendation
TA210 Vascular disease - clopidogrel and dipyridamole (TA210) Y Chapter 2
TA211 Constipation (women) - prucalopride (TA211) Y Chapter 1
TA212 Colorectal cancer (metastatic) - bevacizumab Negative recommendation
TA213 Schizophrenia - aripiprazole (TA213) Y Chapter 4
TA214 Breast cancer - bevacizumab (in combination with a taxane) Negative recommendation
TA215 Renal cell carcinoma (first line metastatic) - pazopanib Y No chapter 8
TA216 Leukaemia (lymphocytic) - bendamustine Y No chapter 8
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217) Y Chapter 4
TA218 Myelodysplastic syndromes - azacitidine Y No chapter 8
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma Negative recommendation
TA220 Psoriatic arthritis - golimumab (TA220) Y Chapter 10
TA221 Thrombocytopenic purpura - romiplostim (TA221) Y No chapter 9
TA223 Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate (TA223)
Y Chapter 2
TA224 Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) Terminated
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225) Y Chapter 10
TA226 Lymphoma (follicular non-Hodgkin's) - rituximab Y No chapter 8
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib
(monotherapy)
Negative recommendation
TA228 Multiple myeloma (first line) - bortezomib and thalidomide Y No chapter 8
TA229 Macular oedema (retinal vein occlusion) - dexamethasone (TA229) Y Chapter 11
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230) Y Chapter 2
TA231 Depression - agomelatine (terminated appraisal) Terminated
TA232 Epilepsy (partial) - retigabine (adjuvant) (TA232) Y Chapter 4
TA233 Ankylosing spondylitis - golimumab (TA233) Replaced by TA383
TA234 Rheumatoid arthritis - abatacept (2nd line) (TA234) Replaced by TA280
TA235 Osteosarcoma - mifamurtide Y No chapter 8
TA236 Acute coronary syndromes - ticagrelor (TA236) Y Chapter 2
TA237 Macular oedema (diabetic) - ranibizumab (TA237) Replaced by TA274
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab Y Chapter 10
TA239 Breast cancer (metastatic) - fulvestrant Negative recommendation
TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal) Terminated
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) Negative recommendation
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) Negative recommendation
TA243 Follicular lymphoma - rituximab (review) Y No chapter 8
TA244 Chronic obstructive pulmonary disease - roflumilast (TA244) Negative recommendation
TA245 Venous thromboembolism - apixaban (hip and knee surgery) (TA245) Y Chapter 2
TA246 Venom anaphylaxis - immunotherapy pharmalgen Y Chapter 3
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247) Y Chapter 10
TA248 Diabetes (type 2) - exenatide (prolonged release) (TA248) replaced by NG28
TA249 Atrial fibrillation - dabigatran etexilate (TA249) Y Chapter 2
TA250 Breast cancer (advanced) - eribulin Negative recommendation
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib Y No chapter 8
TA252 Hepatitis C (genotype 1) - telaprevir (TA252) Y No infections chapter
TA253 Hepatitis C (genotype 1) - boceprevir (TA253) Y No infections chapter
TA254 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254) Y No chapter 8
TA255 Prostate cancer - cabazitaxel Negative recommendation
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256) Y Chapter 2
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase
inhibitor)
Negative recommendation
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) Y No chapter 8
TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a
docetaxel-containing regimen
Y No chapter 8
TA260 Migraine (chronic) - botulinum toxin type A Y Chapter 4
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban Y Chapter 2
TA262 Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) Terminated
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast
cancer
Negative recommendation
TA264 Stroke (acute, ischaemic) - alteplase Y Chapter 2
TA265 Bone metastases from solid tumours - denosumab Y Chapter 6
TA267 Chronic heart failure - ivabradine Y Chapter 2
TA266 Cystic fibrosis - mannitol dry powder for inhalation Y Chapter 3
TA270 Leukaemia (acute myeloid ) - decitabine (terminated appraisal) Terminated
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib Y No chapter 8
TA268 Melanoma (stage III or IV) - ipilimumab Y No chapter 8
TA271 Diabetic macular oedema - fluocinolone acetonide intravitreal implant Negative recommendation
TA273 Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) Terminated
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine Negative recommendation
TA274 Macular oedema (diabetic) - ranibizumab Y Chapter 11
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban Y Chapter 2
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin Y No infections chapter
TA277 Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness
receiving palliative care (terminated appraisal)
Terminated
TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) Y Chapter 3
TA281 Gout - canakinumab (terminated appraisal) Terminated
TA282 Idiopathic pulmonary fibrosis - pirfenidone Replaced by TA504
TA280 Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) Replaced by TA375
TA279 Vertebral fractures - vertebroplasty and kyphoplasty Not drug related
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced
ovarian cancer
Negative recommendation
TA283 Macular oedema (retinal vein occlusion) - ranibizumab Y Chapter 11
TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive
or partially platinum-sensitive) - bevacizumab
Negative recommendation
TA286 Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) Terminated
TA291 Gout (tophaceous, severe debilitating, chronic) - pegloticase Negative recommendation
TA289 Myelofibrosis (splenomegaly, symptoms) - ruxolitinib Negative recommendation
TA290 Overactive bladder - mirabegron Y Chapter 7
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban Y Chapter 2
TA288 Type 2 diabetes - Dapagliflozin combination therapy Y Chapter 6
TA292 Bipolar disorder (children) - aripiprazole Y Chapter 4
TA293 Thrombocytopenic purpura - eltrombopag Y No chapter 9
TA294 Macular degeneration (wet age-related) - aflibercept (1st line) Y Chapter 11
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) -
everolimus (with an aromatase inhibitor)
Negative recommendation
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) -
crizotinib
Negative recommendation
TA297 Vitreomacular traction - ocriplasmin Y Chapter 11
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab Y Chapter 11
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) Y Chapter 11
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin Y No infections chapter
TA302 Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) Terminated
TA299 Leukaemia (chronic myeloid) - bosutinib Negative recommendation
TA303 Multiple sclerosis (relapsing) - teriflunomide Y No chapter 8
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2,
TA44)
Not drug related
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection Y Chapter 11
TA306 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy Y No chapter 8
TA307 Colorectal cancer (metastatic) - aflibercept
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) Y Chapter 10
TA309 Lung cancer (non small cell, non squamous) - pemetrexed Negative recommendation
TA310 Lung cancer (non small cell, EGFR mutation positive) - afatinib Y No chapter 8
TA311 Multiple myeloma - bortezomib (induction therapy) Y No chapter 8
TA312 Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312) Y No chapter 8
TA313 Ustekinumab for treating active psoriatic arthritis (TA313) Negative recommendation
TA314 Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias
and heart failure (review of TA95 and TA120) (TA314)
Not drug related
TA315 Canagliflozin in combination therapy for treating type 2 diabetes (TA315) Y Chapter 6
TA316 Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)
Y No chapter 8
TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
(review of technology appraisal guidance 182)
Y Chapter 2
TA318 Lubiprostone for treating chronic idiopathic constipation Y Chapter 1
TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Y No chapter 8
TA320 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) Y No chapter 8
TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q
cytogenetic abnormality (TA322)
Y No chapter 8
TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)
Y No chapter 8
TA323 Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) (TA323)
Y No chapter 9
TA324 Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88) (TA324)
Not drug related
TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325) Y Chapter 4
TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) (TA326)
Y No chapter 8
TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)
Y Chapter 2
TA328 Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)
Terminated
TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (TA329)
Y Chapter 1
TA330 Sofosbuvir for treating chronic hepatitis C (TA330) Y No infections chapter
TA331 Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)
Y No infections chapter
TA332 Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)
Negative recommendation
TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Y No chapter 8
TA334 Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Terminated
TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)
Y Chapter 2
TA336 Empagliflozin in combination therapy for treating type 2 diabetes (TA336) Y Chapter 6
TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337) Y Chapter 1
TA338 Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)
Negative recommendation
TA339 Omalizumab for previously treated chronic spontaneous urticaria (TA339) Y Chapter 3
TA340 Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) (TA340)
Y Chapter 10
TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)
Y Chapter 2
TA342 Vedolizumab for treating moderately to severely active ulcerative colitis (TA342) Y Chapter 1
TA343 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Y No chapter 8
TA344 Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)
Y No chapter 8
TA346 Aflibercept for treating diabetic macular oedema (TA346) Y Chapter 11
TA351 Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal) (TA351)
Terminated
TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349) Y Chapter 11
TA348 Everolimus for preventing organ rejection in liver transplantation (TA348) Negative recommendation
TA345 Naloxegol for treating opioid-induced constipation (TA345) Y Chapter 1
TA347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347)
Y No chapter 8
TA350 Secukinumab for treating moderate to severe plaque psoriasis (TA350) Y Chapter 13
TA353 Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)
Terminated
TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Y Chapter 2
TA352 Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Y Chapter 1
TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)
Y Chapter 2
TA356 Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
Terminated
TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Y No chapter 8
TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358) Y Chapter 6
TA359 Idelalisib for treating chronic lymphocytic leukaemia (TA359) Y No chapter 8
TA360 Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)
Negative recommendation
TA361 Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)
Terminated
TA362 Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)
Terminated
TA363 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363) Y No infections chapter
TA364 Daclatasvir for treating chronic hepatitis C (TA364)
Y No infections chapter
TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Y No infections chapter
TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) Y No chapter 8
TA367 Vortioxetine for treating major depressive episodes (TA367) Y Chapter 4
TA368 Apremilast for treating moderate to severe plaque psoriasis (TA368) Negative recommendation
TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
Y Chapter 11
TA370 Bortezomib for previously untreated mantle cell lymphoma (TA370) Y No chapter 8
TA371 Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)
Negative recommendation
TA372 Apremilast for treating active psoriatic arthritis (TA372) Negative recommendation
TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Y Chapter 10
TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
Y No chapter 8
HST1 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) Y No Chapter 9
HST2 Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2) Y No Chapter 9
TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Y Chapter 10
TA376 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)
Y No Chapter 8
TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Y No Chapter 8
TA378 Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)
Negative recommendation
TA379 Nintedanib for treating idiopathic pulmonary fibrosis (TA379) Y Chapter 3
TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) Y No Chapter 8
TA381 Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)
Y No Chapter 8
TA382 Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)
Terminated
TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Y Chapter 10
TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) Y No Chapter 8
TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
Y Chapter 2
TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)
Y No Chapter 8
TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Y No Chapter 8
TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Y Chapter 2
TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Y No Chapter 8
TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes Y Chapter 6
TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel Y No Chapter 8
TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa Y Chapter 13
TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Y Chapter 2
TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Y Chapter 2
TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer Y No Chapter 8
TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma Y No Chapter 8
TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus Y Chapter 10
TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation Negative recommendation
TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts Negative recommendation
TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma Y No Chapter 8
HST3 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Y Chapter 10
TA401 Bosutinib for previously treated chronic myeloid leukaemia Y No Chapter 8
TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Y No Chapter 8
TA403 Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer Negative recommendation
TA404 Degarelix for treating advanced hormone-dependent prostate cancer Y Chapter 8
TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer Y No Chapter 8
TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Y No Chapter 8
TA407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Y Chapter 10
TA408 Pegaspargase for treating acute lymphoblastic leukaemia Y No Chapter 8
TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Y Chapter 11
TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma Y No Chapter 8
TA411 Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Negative recommendation
TA412 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Not drug related
TA413 Elbasvir–grazoprevir for treating chronic hepatitis C Y No infections chapter
TA414 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Negative recommendation
TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Y Chapter 10
TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Y No chapter 8
TA417 Nivolumab for previously treated advanced renal cell carcinoma Y No chapter 8
TA418 Dapagliflozin in triple therapy for treating type 2 diabetes Y Chapter 6
TA419 Apremilast for treating moderate to severe plaque psoriasis Y Chapter 13
TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction Y Chapter 2
TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy Y No Chapter 8
TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Y No Chapter 8
TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Y No Chapter 8
TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer Y No Chapter 8
TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Y No Chapter 8
TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia Y No Chapter 8
TA427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib Y No Chapter 8
TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy Y No Chapter 8
TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Y No Chapter 8
TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C Y No infections chapter
TA431 Mepolizumab for treating severe refractory eosinophilic asthma Y Chapter 3
TA432 Everolimus for advanced renal cell carcinoma after previous treatment Y No Chapter 8
HST4 Migalastat for treating Fabry disease Y No Chapter 9
TA433 Apremilast for treating active psoriatic arthritis Y Chapter 10
TA434 Elotuzumab for previously treated multiple myeloma (terminated appraisal) Terminated
TA435 Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) Terminated
TA436 Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
Terminated
TA437 Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
Terminated
TA438 Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Terminated
TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer Y No Chapter 8
TA440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Negative recommendation
TA441 Daclizumab for treating relapsing–remitting multiple sclerosis Y No Chapter 8
TA442 Ixekizumab for treating moderate to severe plaque psoriasis Y Chapter 13
TA443 Obeticholic acid for treating primary biliary cholangitis Y Chapter 1
TA444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Terminated
TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Y Chapter 10
TA446 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma Y No Chapter 8
TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer Y No Chapter 8
TA448 Etelcalcetide for treating secondary hyperparathyroidism Y No Chapter 9
TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Y No Chapter 8
TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Y No Chapter 8
TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia Y No Chapter 8
HST5 Eliglustat for treating type 1 Gaucher disease Y No Chapter 9
TA452 Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Terminated
TA453 Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Terminated
TA454 Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Terminated
TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Y Chapter 13
TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment Y Chapter 1
TA457 Carfilzomib for previously treated multiple myeloma Y No Chapter 8
TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Y No Chapter 8
TA459 Collagenase clostridium histolyticum for treating Dupuytren's contracture Y Chapter 10
TA460 Adalimumab and dexamethasone for treating non-infectious uveitis Y Chapter 11
TA461 Roflumilast for treating chronic obstructive pulmonary disease Y Chapter 3
TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma Y No Chapter 8
TA463 Cabozantinib for previously treated advanced renal cell carcinoma Y No Chapter 8
TA464 Bisphosphonates for treating osteoporosis Y Chapter 6
TA465 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma Y No Chapter 8
TA466 Baricitinib for moderate to severe rheumatoid arthritis Y Chapter 10
TA467 Holoclar for treating limbal stem cell deficiency after eye burns Y Chapter 11
HST6 Asfotase alfa for treating paediatric-onset hypophosphatasia Y No Chapter 9
TA468 Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) Terminated
TA469 Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) Terminated
TA470 Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
Terminated
TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea Y Chapter 1
TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Y No Chapter 8
TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck Y No Chapter 8
TA474 Sorafenib for treating advanced hepatocellular carcinoma Y No Chapter 8
TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis Y Chapter 13
TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Y No Chapter 8
TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
Not drug related
TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Y No Chapter 8
TA479 Reslizumab for treating severe eosinophilic asthma Y Chapter 3
TA480 Tofacitinib for moderate to severe rheumatoid arthritis Y Chapter 10
TA481 Immunosuppressive therapy for kidney transplant in adults Y No Chapter 8
TA482 Immunosuppressive therapy for kidney transplant in children and young people Y No Chapter 8
TA483 Nivolumab for previously treated squamous non-small-cell lung cancer Y No Chapter 8
TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer Y No Chapter 8
TA485 Sarilumab for moderate to severe rheumatoid arthritis Y Chapter 10
TA486 Aflibercept for treating choroidal neovascularisation Y Chapter 11
TA487 Venetoclax for treating chronic lymphocytic leukaemia Y No Chapter 8
TA488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours Y No Chapter 8
TA489 Vismodegib for treating basal cell carcinoma Negative recommendation
TA490 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Y No Chapter 8
TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia Y No Chapter 8
TA492 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Y No Chapter 8
TA493 Cladribine tablets for treating relapsing–remitting multiple sclerosis Y No Chapter 8
TA494 Naltrexone–bupropion for managing overweight and obesity Negative recommendation
TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Y No Chapter 8
TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Y No Chapter 8
TA497 Golimumab for treating non-radiographic axial spondyloarthritis Y Chapter 10
TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma Y No Chapter 8
TA499 Glecaprevir–pibrentasvir for treating chronic hepatitis C Y No infections chapter
TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer Y No Chapter 8
TA501 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer Not drug related
TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma Y No Chapter 8
TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Negative recommendation
TA504 Pirfenidone for treating idiopathic pulmonary fibrosis Y Chapter 3
TA505 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Y No Chapter 8
TA506 Lesinurad for treating chronic hyperuricaemia in people with gout Negative recommendation
TA507 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C Y No infections chapter
TA508 Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Not drug related
TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer Y No Chapter 8
TA510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma Y No Chapter 8
TA511 Brodalumab for treating moderate to severe plaque psoriasis Y Chapter 13
TA512 Tivozanib for treating advanced renal cell carcinoma Y No Chapter 8
TA513 Obinutuzumab for untreated advanced follicular lymphoma Y No Chapter 8
TA514 Regorafenib for previously treated advanced hepatocellular carcinoma Negative recommendation
TA515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Negative recommendation
TA516 Cabozantinib for treating medullary thyroid cancer Y No Chapter 8
TA517 Avelumab for treating metastatic Merkel cell carcinoma Y No Chapter 8
TA518 Tocilizumab for treating giant cell arteritis Y Chapter 10
TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Y No Chapter 8
TA520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Y No Chapter 8
Up-to-date on 31/05/2018